SAFit2 is a highly potent and selective antagonist of FK506-binding protein 51 (FKBP51) with a Ki of 6 nM. It exhibits anxiolytic and antidepressant-like effects, regulates AKT2-AS160 signaling and metabolic function, and may be useful in research on stress-related disorders and type 2 diabetes.

SAFit2 is a highly potent and selective antagonist of FK506-binding protein 51 (FKBP51) with a Ki of 6 nM. It exhibits anxiolytic and antidepressant-like effects, regulates AKT2-AS160 signaling and metabolic function, and may be useful in research on stress-related disorders and type 2 diabetes.

CB-6644 is an allosteric and selective inhibitor of the RUVBL1/2 complex, it blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM. It exhibits anti-cancer activity and demonstrates the therapeutic potential of targeting RUVBLs in the treatment of cancer.

SAFit2 is a highly potent and selective antagonist of FK506-binding protein 51 (FKBP51) with a Ki of 6 nM. It exhibits anxiolytic and antidepressant-like effects, regulates AKT2-AS160 signaling and metabolic function, and may be useful in research on stress-related disorders and type 2 diabetes.

SAFit2 is a highly potent and selective antagonist of FK506-binding protein 51 (FKBP51) with a Ki of 6 nM. It exhibits anxiolytic and antidepressant-like effects, regulates AKT2-AS160 signaling and metabolic function, and may be useful in research on stress-related disorders and type 2 diabetes.

CB-6644 is an allosteric and selective inhibitor of the RUVBL1/2 complex, it blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM. It exhibits anti-cancer activity and demonstrates the therapeutic potential of targeting RUVBLs in the treatment of cancer.

CB-6644 is an allosteric and selective inhibitor of the RUVBL1/2 complex, it blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM. It exhibits anti-cancer activity and demonstrates the therapeutic potential of targeting RUVBLs in the treatment of cancer.

CB-6644 is an allosteric and selective inhibitor of the RUVBL1/2 complex, it blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM. It exhibits anti-cancer activity and demonstrates the therapeutic potential of targeting RUVBLs in the treatment of cancer.

Emzadirib an inhibitor of RAD51 exhibits a reduction in RAD51 foci. Emzadirib displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.

Emzadirib an inhibitor of RAD51 exhibits a reduction in RAD51 foci. Emzadirib displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.